Treatment
The main aim of treatment is enable the individual or couple to enjoy a satisfactory sexual experience. This involves:
- identifying and treating any curable causes of ED
- hormonal
- androgen deficiency – treat with testosterone (cause of hypogonadism should always be sought before treatment with testosterone is initiated)
- men with a total serum testosterone that is consistently <12 nmol/l might benefit from up to a 6 months trial of testosterone replacement therapy for ED
- long-acting (three-monthly) testosterone injection or daily application of a transdermal testosterone gel are acceptable to most men
- hyper/hypothyroidism, hyperprolactinaemia - effective treatment of the underlying cause
- androgen deficiency – treat with testosterone (cause of hypogonadism should always be sought before treatment with testosterone is initiated)
- post-traumatic arteriogenic ED in young patients - penile revascularization
- drug-induced ED - withdrawing or changing a drug suspected of causing sexual dysfunction may reduce ED (it is important not to compromise the effective management of another important condition)
- partner sexual problems – identify and address co-existing sexual problems in the partner
- radical prostatectomy - early introduction of pharmacotherapy
- hormonal
- initiating lifestyle change and risk factor modification
- should accompany any specific pharmacotherapy or psychological therapy (however, pharmacotherapy should not be withheld on the basis that lifestyle changes have not been made)
- beneficial especially in those with psychogenic ED, but patients with serious medical illnesses such as diabetes may also benefit from these changes, e.g. weight loss
- simple lifestyle measures such as regular exercise, smoking cessation, and weight loss can be recommended for men with these risk factors who have mild erectile dysfunction
- providing psychosexual/ relationship therapy, counselling to patients and their partners
- group or individual cognitive behavior therapy; psychosexual therapy, including sensate focus technique; and therapy aimed at improving relationship difficulties may help to improve sexual dysfunction in men (3)
Treatments options available in ED include:
- first line treatment
- PDE5 inhibitors (e.g. sildenafil, tadalafil, vardenafil)
- sildenafil and vardenafil are relatively short-acting drugs while tadalafil has a significantly longer half life of 17.5 hours
- are not initiators of erection but require sexual stimulation in order to facilitate an erection
- contraindicated in patients who are receiving nitrate preparations
- it is currently recommended that patients should receive eight doses of a PDE5 inhibitor with sexual stimulation at maximum dose before classifying a patient as a non-responder
- vacuum erection devices:
- are highly effective in inducing erections regardless of the aetiology of the ED
- reported satisfaction rates vary considerably from 35% to 84%
- adverse effects include bruising, local pain, and failure to ejaculate. Partners sometimes report the penis feels cold
- PDE5 inhibitors (e.g. sildenafil, tadalafil, vardenafil)
- second line treatment - available in secondary care
- intracavernous Alprostadil (synthetic prostaglandin E1 analogue) injection
- intraurethral Alprostadil
- third line treatment
- penile prostheses
Other therapies available for treatment of ED (unlicensed products)
- yohombine
- delaquamine
- trazodone
- L-arginine
- red Korea
- ginseng
- oral limaprost
- oral phentolamine and nitroglycerine
- papaverine
- minoxidil topically (4)
Reference:
- (1) Hackett G et al. British Society for Sexual Medicine guidelines on the management of erectile dysfunction. J Sex Med. 2008;5(8):1841-65.
- (2) Muneer A et al. Erectile dysfunction. BMJ. 2014;348:g129
- (3) Heidelbaugh JJ. Management of erectile dysfunction. Am Fam Physician. 2010;81(3):305-12
- (4) Clinical Evidence. BMJ March 2006.
Related pages
- Intracavernosal injections
- Sildenafil citrate (oral therapy)
- Apomorphine for erectile dysfunction
- Transurethral alprostadil
- Referral criteria from primary care - erectile dysfunction (ED)
- Vacuum erection devices
- Penile prostheses
- Tadalafil
- Yohimbe bark
- Ginseng for erectile dysfunction
- NICE guidance - erectile dysfunction in type 2 diabetes
- Eligible groups for NHS funding for erectile dysfunction (ED)
- Low-intensity extracorporeal shockwave therapy (Li-ESWT) and erectile dysfunction (ED)
- Eroxon (MED3000) - topical GTN (glyceryl trinitrate) - for erectile dysfunction (ED)
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.